The Advance of Clinical Pharmacology in Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 20 April 2025 | Viewed by 30
Special Issue Editors
2. Chair, School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
3. Chair, Lung Cancer Team, Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Interests: lung cancer; target therapy; immunotherapy; antiangiogenic agent; chemotherapy; NGS
Special Issues, Collections and Topics in MDPI journals
Interests: lung cancer; molecular biology; target therapy; animal models
Special Issue Information
Dear Colleagues,
Lung cancer has always been the deadliest cancer worldwide, largely due to its difficult detection, meaning that it is often only discovered in its advanced stages. Since the development of EGFR TKI-targeted therapy, precision medicine in lung cancer has been increasingly implemented. With the integration of next-generation sequencing (NGS) technologies, various driver genes have been validated in clinical trials and real-world data, showing significant improvements in patient response rates, disease progression-free periods, and even survival rates compared to traditional chemotherapy. Beyond targeted therapies, the combined use of anti-angiogenesis drugs and the development of immunotherapy have set milestones in lung cancer treatment. These advances apply not only to systemic treatments in stage four lung cancer but also to earlier-stage lung cancer patients receiving neoadjuvant or adjuvant therapy, bringing hope for long-term survival. In this Special Issue, we aim to further explore and discuss the pharmacological aspects and usage of these drugs, hoping to contribute to the treatment of lung cancer.
Prof. Dr. Chih-Jen Yang
Dr. Yen-Yi Zhen
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- target therapy
- immunotherapy
- antiangiogenic agent
- chemotherapy
- NGS
